|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The recently published BP treatment guidelines by the American College of Cardiology/American Heart Association (ACC/AHA) recommend a systolic BP (SBP) and diastolic BP reduction to less than 130 mmHg and less than 80 mmHg, respectively, for all ages, and have also changed the classification of hypertension by changing the term "prehypertension" of the JNC 7 (7th Joint National Committee) guidelines to "stage 1 hypertension".
|
31050695 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
This Kidney Disease Outcomes Quality Initiative (KDOQI) commentary focuses largely on recommendations from the ACC/AHA hypertension guidelines that are pertinent to individuals at risk of chronic kidney disease or with non-dialysis-dependent chronic kidney disease.
|
30905361 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Approximately 17.0% and 40.1% of participants met the respective definitions of hypertension according to Joint National Committee 7 (JNC7) and 2017 American College of Cardiology/American Heart Association (ACC/AHA) Hypertension Guideline.
|
31382808 |
2020 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Status of Hypertension in Tehran: Potential impact of the ACC/AHA 2017 and JNC7 Guidelines, 2012-2015.
|
31011156 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Using the adapted ACC/AHA BPM procedure compared to the CHEP BPM procedure led to an increase in the AHT prevalence rate (≥130/80 mm Hg) of 4% (58% vs. 54%).
|
30371728 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Impact of the new criteria of the ACC/AHA on the diagnostic prevalence of hypertension.
|
31481243 |
2020 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Significant predictors of F-ACC-12 and 24 included age and hypertension.
|
28111356 |
2017 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Blood pressure and the new ACC/AHA hypertension guidelines.
|
31521481 |
2020 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Baseline prevalence of hypertension under the AHA/ACC 2017 threshold in participants entering the data set between 20 and 30 years of age was 30.7% in white men (n = 549 of 1790), 23.1% in African American men (n = 245 of 1063), 10.2% in white women (n = 210 of 2070), and 12.3% in African American women (n = 171 of 1390).
|
30916719 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome.
|
30827526 |
2019 |
|
Cardiovascular Diseases
|
0.080 |
Biomarker
|
group |
BEFREE |
In an HIV clinical care cohort, the ACC/AHA cholesterol guidelines recommend a higher proportion of patients for statin therapy and identify an increased proportion of patients with a CVD event compared with ATPIII.
|
30619912 |
2018 |
|
Cardiovascular Diseases
|
0.080 |
Biomarker
|
group |
BEFREE |
We used the Cardiovascular Disease Policy Model to estimate the cost-effectiveness of the ACC/AHA guideline relative to current use, Adult Treatment Panel III guidelines, and universal statin use in all men 45 to 74 years of age and women 55 to 74 years of age over a 10-year horizon from 2016 to 2025.
|
28687710 |
2017 |
|
Cardiovascular Diseases
|
0.080 |
Biomarker
|
group |
BEFREE |
However, the reclassification improvement was not substantially different between model 6 and the ACC/AHA CVD Pooled Cohort risk equations or between model 6 and the FHS.
|
27437649 |
2016 |
|
Cardiovascular Diseases
|
0.080 |
Biomarker
|
group |
BEFREE |
Eligible patients of enrolled primary care providers are aged 40-75 and have elevated risk of cardiovascular disease by American College of Cardiology/American Heart Association (ACC/AHA) guidelines.
|
30367991 |
2018 |
|
Cardiovascular Diseases
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Haploview analysis showed that the ACC (rs151290, rs2237892 and rs2237895) haplotype is the most significant risk allele combination for CVD, while CCA is the most significant risk haplotype for co-morbidity with T2D.
|
28863213 |
2019 |
|
Cardiovascular Diseases
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Initiating cholesterol-lowering medications for primary prevention, as specified in the ACC/AHA 2013 guidelines, for patients with high LDL-C and diabetes is associated with reduced CVD event risks and lower health care costs.
|
30362921 |
2018 |
|
Cardiovascular Diseases
|
0.080 |
Biomarker
|
group |
BEFREE |
Ten-year CVD risk was estimated with American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease (ACC/AHA ASCVD) Risk Estimator (2013), Framingham Risk Score (Framingham Risk Score [FRS] 2008), and the World Health Organisation/International Society of Hypertension (WHO/ISH) risk prediction chart for Africa Region D. Kappa statistic was used to determine agreement among the estimators.
|
29050979 |
2018 |
|
Cardiovascular Diseases
|
0.080 |
Biomarker
|
group |
BEFREE |
Relationship of the Blood Pressure Categories, as Defined by the ACC/AHA 2017 Blood Pressure Guidelines, and the Risk of Development of Cardiovascular Disease in Low-Risk Young Adults: Insights From a Retrospective Cohort of Young Adults.
|
31140347 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Adenoid cystic primary pulmonary carcinomas (adenoid cystic carcinomas or ACCs) are rare tumors, so we described the clinical and pathological features of these tumors and related these findings with diagnosis and prognosis of ACC, comparing our data to the existing literature.
|
26261681 |
2015 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
ACC is a relatively rare tumor associated
|
29653784 |
2018 |
|
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Mutation and expression analyses demonstrated that the tumor suppressor gene NF2, which is known to be one of the most frequently mutated in MPM, is mutated in ACC-MESO-1.
|
16630136 |
2006 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The proliferation in vitro of ACC-M cells and subcutaneous tumor growth of nude mice was inhibited by XAGE-1b interference.
|
24008415 |
2013 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Subsequent analyses of clinical patient samples confirmed a correlation between tumor TNFAIP3 expression levels and overall survival in patients with ACC.
|
26768118 |
2016 |
|
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
We found missense mutations of AAC (Asn) to AGC (Ser) at DCC codon 176 in one cell line and ACC (Thr) to ATC (Ile) at codon 1105 in one cell line and tumor, respectively; polymorphisms of CGA (Arg) to GGA (Gly) at codon 201 and TTT (Phe) to TTG (Leu) at codon 951 in most of the cell lines and tumors; and a silent mutation of GAG (Glu) to GAA (Glu) at codon 118 in four cell lines and five primary tumors.
|
9288786 |
1997 |
|
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
We found that 15 out of 16 tumor-associated virus isolates sequenced encoded an ATT or ACC codon in place of ATG in the LMP-1 ORF at position 129, and tumor cell lines harboring isolates lacking an ATG at codon 129 did not express the lyLMP-1 protein.
|
12634399 |
2003 |